Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmeris… Read more
Fagron NV (ARSUF) - Total Liabilities
Latest total liabilities as of June 2025: $613.74 Million USD
Based on the latest financial reports, Fagron NV (ARSUF) has total liabilities worth $613.74 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fagron NV - Total Liabilities Trend (2013–2024)
This chart illustrates how Fagron NV's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Fagron NV Competitors by Total Liabilities
The table below lists competitors of Fagron NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coca-Cola Bottlers Japan Holdings Inc
OTCGREY:CCOJF
|
USA | $2.18 Billion |
|
Nationwide Building Society
LSE:NBS
|
UK | £358.92 Billion |
|
The Gunma Bank Ltd
OTCGREY:GMBKF
|
USA | $10.07 Trillion |
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
Mexico | MX$43.64 Billion |
|
De'Longhi S.p.A
OTCGREY:DELHF
|
USA | $1.81 Billion |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
China | CN¥5.61 Billion |
|
Fabege AB
ST:FABG
|
Sweden | Skr45.61 Billion |
|
Amprius Technologies Inc.
NYSE:AMPX
|
USA | $53.28 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Fagron NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fagron NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fagron NV (2013–2024)
The table below shows the annual total liabilities of Fagron NV from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $578.16 Million | +7.20% |
| 2023-12-31 | $539.33 Million | -4.10% |
| 2022-12-31 | $562.38 Million | +18.41% |
| 2021-12-31 | $474.95 Million | -4.05% |
| 2020-12-31 | $495.01 Million | -10.78% |
| 2019-12-31 | $554.80 Million | +17.28% |
| 2018-12-31 | $473.06 Million | +15.61% |
| 2017-12-31 | $409.17 Million | -42.79% |
| 2016-12-31 | $715.18 Million | -5.17% |
| 2015-12-31 | $754.15 Million | -23.68% |
| 2014-12-31 | $988.15 Million | +52.13% |
| 2013-12-31 | $649.52 Million | -- |